Pharmacotherapy of Depressed Children and Adolescents: Current Issues and Potential Directions

Roma A Vasa, Anthony R. Carlino, Daniel S. Pine

Research output: Contribution to journalArticle

Abstract

The recent deliberations by the U.S. Food and Drug Administration (FDA) regarding the relationship between antidepressants and suicidality in children have incited debates about the safety of these medications for the treatment of pediatric depression. In light of these events, this review discusses four issues pertaining to pharmacotherapy for pediatric depression. First, we summarize pertinent data from randomized controlled trials of antidepressants for pediatric depression. These data provide strong support for fluoxetine and modest support for the other antidepressants. Second, we examine the outcome of the FDA meta-analysis of the data on antidepressant-induced suicidality, with specific emphasis on the methodological limitations of this analysis. Third, we consider the collective implications of the antidepressant efficacy and suicidality data on clinical practice. Specifically, we present several compelling arguments that justify the continued use of antidepressants for pediatric depression, despite the inherent limitations of these medications. Finally, we review several pathophysiological factors that might provide insights into treatment response and impact the design of future pharmacotherapy studies of depression. These factors relate to diagnostic heterogeneity, developmental consistency, and psychobiology. Potentially novel pharmacotherapies are also discussed.

Original languageEnglish (US)
Pages (from-to)1021-1028
Number of pages8
JournalBiological Psychiatry
Volume59
Issue number11
DOIs
StatePublished - Jun 1 2006

Fingerprint

Antidepressive Agents
Drug Therapy
Pediatrics
United States Food and Drug Administration
Fluoxetine
Meta-Analysis
Direction compound
Randomized Controlled Trials
Safety
Therapeutics

Keywords

  • clinical trials
  • Major depression
  • pediatric, antidepressants

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Pharmacotherapy of Depressed Children and Adolescents : Current Issues and Potential Directions. / Vasa, Roma A; Carlino, Anthony R.; Pine, Daniel S.

In: Biological Psychiatry, Vol. 59, No. 11, 01.06.2006, p. 1021-1028.

Research output: Contribution to journalArticle

Vasa, Roma A ; Carlino, Anthony R. ; Pine, Daniel S. / Pharmacotherapy of Depressed Children and Adolescents : Current Issues and Potential Directions. In: Biological Psychiatry. 2006 ; Vol. 59, No. 11. pp. 1021-1028.
@article{a94d1b750607470f9df697efb075f3ac,
title = "Pharmacotherapy of Depressed Children and Adolescents: Current Issues and Potential Directions",
abstract = "The recent deliberations by the U.S. Food and Drug Administration (FDA) regarding the relationship between antidepressants and suicidality in children have incited debates about the safety of these medications for the treatment of pediatric depression. In light of these events, this review discusses four issues pertaining to pharmacotherapy for pediatric depression. First, we summarize pertinent data from randomized controlled trials of antidepressants for pediatric depression. These data provide strong support for fluoxetine and modest support for the other antidepressants. Second, we examine the outcome of the FDA meta-analysis of the data on antidepressant-induced suicidality, with specific emphasis on the methodological limitations of this analysis. Third, we consider the collective implications of the antidepressant efficacy and suicidality data on clinical practice. Specifically, we present several compelling arguments that justify the continued use of antidepressants for pediatric depression, despite the inherent limitations of these medications. Finally, we review several pathophysiological factors that might provide insights into treatment response and impact the design of future pharmacotherapy studies of depression. These factors relate to diagnostic heterogeneity, developmental consistency, and psychobiology. Potentially novel pharmacotherapies are also discussed.",
keywords = "clinical trials, Major depression, pediatric, antidepressants",
author = "Vasa, {Roma A} and Carlino, {Anthony R.} and Pine, {Daniel S.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.biopsych.2005.10.010",
language = "English (US)",
volume = "59",
pages = "1021--1028",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Pharmacotherapy of Depressed Children and Adolescents

T2 - Current Issues and Potential Directions

AU - Vasa, Roma A

AU - Carlino, Anthony R.

AU - Pine, Daniel S.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - The recent deliberations by the U.S. Food and Drug Administration (FDA) regarding the relationship between antidepressants and suicidality in children have incited debates about the safety of these medications for the treatment of pediatric depression. In light of these events, this review discusses four issues pertaining to pharmacotherapy for pediatric depression. First, we summarize pertinent data from randomized controlled trials of antidepressants for pediatric depression. These data provide strong support for fluoxetine and modest support for the other antidepressants. Second, we examine the outcome of the FDA meta-analysis of the data on antidepressant-induced suicidality, with specific emphasis on the methodological limitations of this analysis. Third, we consider the collective implications of the antidepressant efficacy and suicidality data on clinical practice. Specifically, we present several compelling arguments that justify the continued use of antidepressants for pediatric depression, despite the inherent limitations of these medications. Finally, we review several pathophysiological factors that might provide insights into treatment response and impact the design of future pharmacotherapy studies of depression. These factors relate to diagnostic heterogeneity, developmental consistency, and psychobiology. Potentially novel pharmacotherapies are also discussed.

AB - The recent deliberations by the U.S. Food and Drug Administration (FDA) regarding the relationship between antidepressants and suicidality in children have incited debates about the safety of these medications for the treatment of pediatric depression. In light of these events, this review discusses four issues pertaining to pharmacotherapy for pediatric depression. First, we summarize pertinent data from randomized controlled trials of antidepressants for pediatric depression. These data provide strong support for fluoxetine and modest support for the other antidepressants. Second, we examine the outcome of the FDA meta-analysis of the data on antidepressant-induced suicidality, with specific emphasis on the methodological limitations of this analysis. Third, we consider the collective implications of the antidepressant efficacy and suicidality data on clinical practice. Specifically, we present several compelling arguments that justify the continued use of antidepressants for pediatric depression, despite the inherent limitations of these medications. Finally, we review several pathophysiological factors that might provide insights into treatment response and impact the design of future pharmacotherapy studies of depression. These factors relate to diagnostic heterogeneity, developmental consistency, and psychobiology. Potentially novel pharmacotherapies are also discussed.

KW - clinical trials

KW - Major depression

KW - pediatric, antidepressants

UR - http://www.scopus.com/inward/record.url?scp=33744915254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744915254&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2005.10.010

DO - 10.1016/j.biopsych.2005.10.010

M3 - Article

C2 - 16406250

AN - SCOPUS:33744915254

VL - 59

SP - 1021

EP - 1028

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 11

ER -